PDF herunterladen
Zeitschrift für Orthomolekulare Medizin 2008; 6(4): 22-26
DOI: 10.1055/s-2008-1039099
Praxistipps

© Hippokrates Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Prävention und Therapie bei Entzündungen

Wilfried P. Bieger
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
05. Dezember 2008 (online)

    Lizenzen und Reprints

Abb. 1 Rote Weintrauben enthalten Resveratrol, das u. a. antientzündliche Wirkung aufweist. Quelle: Rike/PIXELIO.

Entzündliche Mechanismen sind nach heutiger Kenntnis an allen bedeutenden chronischen Krankheiten beteiligt, wenn nicht deren Ursache. Dies trifft nicht nur für die klassischen chronischen Entzündungskrankheiten wie rheumatoide Arthritis, Kollagenosen, Morbus Crohn oder multiple Sklerose zu, sondern ebenso für die atypischen inflammatorischen Erkrankungen wie Adipositas, metabolisches Syndrom, Arteriosklerose, Hypertonus, Herzinfarkt, Schlaganfall, Krebserkrankungen, Neurodegeneration, Alzheimer [10], endogene Depression und selbst für den Alterungsprozess, für den der Begriff „Inflammaging“ geprägt wurde [12].

Nach erfolgreicher Elimination einer Noxe muss im typischen Erkrankungsfall das Entzündungsprogramm möglichst effektiv beendet werden, um Schäden für den betroffenen Organismus zu vermeiden. Das hierfür verfügbare antientzündliche Repertoire ist ähnlich umfangreich wie die proentzündlichen Mechanismen und wirkt selbstlimitierend. Bei den chronischen Entzündungskrankheiten gilt es in erster Linie, die inflammatorische Aktivität zu limitieren bzw. bei den atypischen Erkrankungen, den Entzündungstrigger zu identifizieren und durch primär oder sekundär präventive Maßnahmen möglichst frühzeitig zu eliminieren, um unausweichliche spätere Schäden zu vermeiden.

Literatur

  • 1 Anand P, Sundaram C, Jhurani S. et al . Curcumin and cancer: an “old-age” disease with an “age-old” solution.  Cancer Lett. 2008;  267 133-164
    CrossrefPubMedGoogle Scholar
  • 2 Babu P V, Liu D. Green tea catechins and cardiovascular health: an update.  Curr Med Chem. 2008;  15 1840-1850
    CrossrefGoogle Scholar
  • 3 Boots A W, Wilms L C, Sweenen E L, Kleinjans J C, Bast A, Haenen G R. In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers.  Nutrition. 2008;  24 703-710
    CrossrefGoogle Scholar
  • 4 Bosscher de K, Berghe van den W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression.  Endocr Rev. 2003;  24 488-522
    CrossrefGoogle Scholar
  • 5 Boswellia serrata. Monograph.  Altern Med Rev. 2008;  13 165-167
    Google Scholar
  • 6 Breslow J L. n-3 Fatty acids and cardiovascular disease.  Am J Clin Nutr. 2006;  83 (Suppl) 1477S-1482S
    Google Scholar
  • 7 Calabro P, Yeh E T. Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ.  Subcell Biochem. 2007;  42 63-91
    Google Scholar
  • 8 Calder P. n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases.  Am J Clin Nutr. 2006;  83 (Suppl) 1505S-1519S
    CrossrefPubMedGoogle Scholar
  • 9 Charo I F, Ransohoff R M. The many roles of chemokines and chemokine receptors in inflammation.  New Engl J Med. 2006;  354 610-621
    CrossrefGoogle Scholar
  • 10 Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins.  Lancet. 2004;  363 1139-1146
    CrossrefGoogle Scholar
  • 11 Devaraj S, Leonard S, Traber M G, Jialal I. Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome.  Free Radic Biol Med. 2008;  44 1203-1208
    CrossrefGoogle Scholar
  • 12 Franceschi C. Inflammaging as a major characteristic of old people: can it be prevented or cured?.  Nutr Rev. 2007;  65 S173-S176
    CrossrefGoogle Scholar
  • 13 Giannoulis-Karantara A, Vlachou A, Polychronopoulou S, Papassotiriou I, Chrousos G Pl. Melatonin and immunomodulation: connections and potential clinical applications.  Neuroimmunomodulation. 2006;  13 133-144
    CrossrefGoogle Scholar
  • 14 Goodfellow J, Bellamy M F, Ramsey M W, Jones C J, Lewis M J. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia.  J Am Coll Cardiol. 2000;  35 265-270
    CrossrefGoogle Scholar
  • 15 Hämälainen M, Nieminen R, Vuorela P, Heinonen M, Moilanen E. Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages.  Mediators Inflamm. 2007;  ID 45673 1-10
    Google Scholar
  • 16 Hankey G J, Eikelboom J W. Aspirin resistance.  Lancet. 2006;  367 606-617
    CrossrefGoogle Scholar
  • 17 Hansson G K. Inflammation, atherosclerosis, and coronary artery disease.  New Engl J Med. 2005;  352 1685-1695
    CrossrefGoogle Scholar
  • 18 Harris S G, Padilla J, Koumas L, Ray D, Phipps R P. Prostaglandins as modulators of immunity.  Tr Immunol. 2002;  23 144-150
    CrossrefGoogle Scholar
  • 19 Hatcher H, Planalp R, Cho J. et al . Curcumin: from ancient medicine to current clinical trials.  Cell Mol Life Sci. 2008;  65 1631-1652
    CrossrefGoogle Scholar
  • 20 Jurenka J S. Therapeutic applications of pomegranate (Punica granatum): a review.  Altern Med Rev. 2008;  13 128-144
    Google Scholar
  • 21 Kaisho T, Tanaka T. Turning NF-kB and IRFs on and off in DC.  Tr Immunol. 2008;  29 329-336
    Google Scholar
  • 22 Karlsec A, Rettersol L, Laake P. et al . Anthocyanins inhibit nuclear factor-kB activation in monocytes and reduce olasma concentrations of pro-inflammatory mediators in healthy adults.  J Nutr. 2007;  137 1951-1954
    Google Scholar
  • 23 Lambert C P, Wright N R, Finck B N, Villareal D T. Exercise but not diet-induced weight loss decreases skeletal muscle inflammatory gene expression in frail obese eldely persons.  J Appl Physiol. 2008;  105 473-478
    CrossrefGoogle Scholar
  • 24 Lansky E P, Newman R A. Punica franatum (pomegranate) and its potential for prevention and treatment of infammation and cancer.  J Ethnopharmacol. 2007;  109 177-206
    CrossrefGoogle Scholar
  • 25 Mihm S, Galter D, Dröge W. Modulation of transcription factor NF-kB activity by intracellular glutathione levels and by variations of the extracellular cysteine supply.  Faseb J. 1995;  9 246-252
    Google Scholar
  • 26 Müller N, Schwarz M J. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy. Schizophrenia and major depression as inflammatory CNS disorders.  Eur Arch Psychiatry Neurosci. 2008;  258 (Suppl 2) 97-106
    Google Scholar
  • 27 Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin.  Cancer Lett. 2008;  269 315-325
    CrossrefGoogle Scholar
  • 28 Murias M, Handler N, Erker T. et al . Resveratrol analogues as selective cyclooxygenase-2 inhibitors: snythesis and structure-activity relationship.  Bioorg Med Chem. 2004;  12 5571-5578
    CrossrefPubMedGoogle Scholar
  • 29 Pascual G, Glass C K. Nuclear receptors versus inflammation: mechanisms of transrepression.  Trends Endocrinol Metab. 2006;  17 321-327
    CrossrefGoogle Scholar
  • 30 Petersen A MW, Pedersen B K. The role of IL-6 in mediating the antiinflammatory effects of exercise.  J Physiol Pharmacol. 2006;  57 (Suppl 10) 43-51
    Google Scholar
  • 31 Rainsford K D. Anti-inflammatory drugs in the 21st century.  Subcell Biochem. 2007;  42 3-27
    Google Scholar
  • 32 Redwine L, Hauger R L, Gillin J C, Irwin M. Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans.  J Clin Endocrinol Metab. 2000;  85 3597-3603
    CrossrefPubMedGoogle Scholar
  • 33 Sears B. The antiinflammation zone: reversing the silent epidemic that's destroying our health. Regan Books 2005
    Google Scholar
  • 34 Serhan C N, Brain S D, Buckley C D. et al . Resolution of inflammation: state of the art, definitions and terms.  Faseb J. 2007;  21 325-332
    CrossrefGoogle Scholar
  • 35 Shoelson S E, Lee J, Goldfine A B. Inflammation and insulin resistance.  J Clin Invest. 2006;  116 1793-1801
    CrossrefPubMedGoogle Scholar
  • 36 Song Y, Li T Y, van Dam R M, Manson J E, Hu F B. Magnesium intake and plasma concentrations of markers of systemic inflammation and endothelial dysfunction in women.  Am J Clin Nutr. 2007;  85 1068-1074
    Google Scholar
  • 37 Takada Y, Bhardwaj A, Potdar P, Aggarwal B B. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kB activation, inhibition of cyclooxygenase-2 and cyclin-1, and abrogation of tumor cell proliferation.  Oncogene. 2004;  23 9247-9258
    Google Scholar
  • 38 Tracey K J. Physiology and immunology of the cholinergic antiinflammatory pathway.  J Clin Invest. 2007;  117 289-296
    CrossrefGoogle Scholar
  • 39 Vegeto E, Benedusi V, Maggi A. Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases.  Front Neuroendocrinol. 2008;  29 507-519
    CrossrefGoogle Scholar
  • 40 Zhang W J, Frei B. Alpha-lipoic acid inhibits TNF-alpha induced NF-kB activation and adhesion molecule-1 expression in huma aortic endothelial cells.  Faseb J. 2001;  15 2423-2432
    CrossrefGoogle Scholar

PD Dr. med. Wilfried P. Bieger

Paul-Heyse-Straße 6

80336 München

eMail: wbieger@lab4more.de

      >